ArticleNature reviews. Clinical oncology2021
Immunotherapy biomarkers: the long and winding road.
Article in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- FBLN2 promoter hypermethylation: a negative prognostic biomarker and anti-PD-1 response predictor in clear cell renal cell carcinoma via high-throughput CpG Island screening.Clinical epigenetics · 2025Article
- Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources.Genomics, proteomics & bioinformatics · 2025Review
- The artificial intelligence revolution in gastric cancer management: clinical applications.Cancer cell international · 2025Review
- An Overview of Analytical Approaches to Cancer Proteogenomics.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Recent insights into crosstalk between genetic parasites and their host genome.Briefings in functional genomics · 2024Review
- KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.Journal for immunotherapy of cancer · 2023Article
- A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.Journal for immunotherapy of cancer · 2023Article
- Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.International journal of molecular sciences · 2023Review
- Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.Molecular oncology · 2023Article
- Identification and Validation ofCells · 2022Article
- Article
- Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33727676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.